Determine applicability by product and trading-partner role; do not assume every clinic has identical obligations. For applicable transactions, verify authorized trading partners, required tracing records and suspect-product procedures. FDA’s pharmacy guidance describes these responsibilities. (fda.gov)
There is an important current-date distinction: FDA has published an additional small-business-dispenser exemption period extending certain requirements from November 27, 2026 through November 27, 2027. It does not exempt all parties or eliminate every verification requirement. (fda.gov)
Ask counsel and supply-chain leadership to document:
- The entity’s role in each transaction.
- Whether the product and transaction fall within scope.
- Which requirements apply now.
- Any exemption relied upon and evidence of eligibility.
- Which obligations remain despite that exemption.
- Where records reside and who can retrieve them during a recall.
Do not use a network’s prescriber count as a proxy for eligibility under a dispenser-specific exemption.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients?utm_source=openai
- fda.gov · Source 2 ↗https://www.fda.gov/media/194424/download?trk=public_post_comment-text